Patrys Limited (PAB.AX)
Patrys Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Nedlands, WA, AU. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $11.2M. Its beta of 1.26 implies it has historically moved more than the broad market.
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Patrys Limited is most often compared with the following Healthcare names: